|
Session 153
Poster Abstracts
Lypoatrophy/Lipohypertrophy: Predictors and Interventions
Monday, 1-4 pm
Room: Hall B |
| 935 |
Clinical Associations of Extremity Fat Loss: ACTG 5142, a Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for ART of Naive, HIV-1-infected Subjects
Richard Haubrich*1, S Riddler2, G DiRienzo3, Y Zheng3, W Powderly4, K Garren5, D Butcher6, J Rooney7, J Mellors2, D Havlir8, and the AIDS Clinical Trials Group 5142 Study Team
1Univ of California, San Diego, US; 2Univ of Pittsburgh, PA, US; 3Harvard Sch of Publ Hlth, Statistical and Data Analysis Ctr, Boston, MA, US; 4Univ Coll Dublin, Ireland; 5Abbott Labs, Abbott Park, IL, US; 6Bristol-Myers Squibb, Plainsboro, NJ, US; 7Gilead Sci, Foster City, CA, US; and 8Univ of California, San Francisco, US |
936
 |
Chromium Supplementation Decreases Insulin Resistance and Trunk Fat
E Aghdassi, Irving Salit*, S Mohammed, B Arendt, and J Allard
Univ Hlth Network, Toronto, Canada |
937
|
ZDV/3TC/LPV/r, but Not NVP/LPV/r, Is Associated with Limb Fat Loss and Relative Abdominal Fat Accumulation after 24 Months in ATT-naïve HIV-1-infected Men: MEDICLAS, a Randomized Clinical Trial
Marit GA van Vonderen*1, M van Agtmael1, E Hassink2, A Milinkovic3, K Brinkman4, S Geerlings5, M Ristola6, A van Eeden7, S Danner1, P Reiss5, and the MEDICLAS study group
1VU Univ Med Ctr, Amsterdam, The Netherlands; 2Intl Antiviral Therapy Evaluation Ctr, Amsterdam, The Netherlands; 3Hosp Clin, Barcelona, Spain; 4Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; 5Academic Med Ctr, Univ of Amsterdam, The Netherlands; 6Helsinki Univ Central Hosp, Finland; and 7Medisch Centrum Jan van Goyen, Amsterdam, the Netherlands |
938
|
Switching from Combivir to Truvada Preserves Limb Fat: Results of a DEXA Sub-Study of a 48-Week Randomized Study
Graeme Moyle*1, M Fisher2, and SWEET Study Group
1Chelsea and Westminster Hosp, London, UK and 2Brighton and Sussex Univ Hosp, Brighton, UK |
939
|
Influence of NRTI Choice and Efavirenz vs Lopinavir Treatment Options on Lipoatrophy-associated Adipose Tissue Toxicity: A Longitudinal Study
E Hammond, B McKinnon, C Pace, D Nolan, and Simon Mallal*
Murdoch Univ, and Royal Perth Hosp, Australia |
940
|
Changes in Body Composition Attributable to Lamivudine, Stavudine, Zidovudine, and Abacavir in HIV-infected Persons Initiating ART
Judith Shlay*1, S Sharma2, G Bartsch2, G Peng2, C Gibert3, C Grunfeld4, and the CPCRA and INSIGHT.
1Denver CPCRA, Denver Publ Hlth, CO, US; 2Univ of Minnesota, Minneapolis, US; 3Wide-Reaching AIDS Prgm, VAMC and George Washington Univ, Washington, DC, US; and 4VAMC and Univ of California, San Francisco, US |
941
|
How Much Fat Loss Is Needed for Lipoatrophy to Become Clinically Evident?
Daniel Podzamczer*1, E Ferrer1, E Martinez2, L del Rio3, I Ruiz1, J Rosales3, E Ribera4, P Barrufet5, J Llibre6, M Aranda7, and the ABCDE Study Team
1Hosp Univ de Bellvitge, Barcelona, Spain; 2Hosp Clin, Barcelona, Spain; 3CETIR, Barcelona, Spain; 4Hosp Vall d`Hebron, Barcelona, Spain; 5Hosp de Mataro, Barcelona, Spain; 6Hosp Germans Trials i Pujol, Badalona, Spain; and 7Hosp de Terrassa, Barcelona, Spain |
942
|
Relationship of NRTI-mediated Mitochondrial DNA Depletion and Respiratory Chain Activity in Primary Human Subcutaneous Adipocytes
Metodi Stankov*, R Schmidt, G Behrens, and The German Competence Network HIV/AIDS
Hannover Med Sch, Germany |
943
|
Data on 52-Week Safety and Efficacy of Tesamorelin, a Growth Hormone-releasing Factor Analogue, in HIV-infected Patients with Abdominal Fat Accumulation
J Falutz1, S Allas2, J C Mamputu2, D Kotler3, M Somero4, D Berger5, S Brown6, G Richmond7, J Fessel8, and Steven Grinspoon*9
1Montreal Gen Hosp, McGill Univ Hlth Ctr,Canada; 2Theratechnologies Inc, Montreal, Canada; 3St Luke`s Roosevelt Hosp Ctr, Columbia Univ Coll of Physicians and Surgeons, New York, NY, US; 4Palm Springs, CA, US; 5Northstar Hlth Care, Chicago, IL, US; 6AIDS Res Alliance, West Hollywood, CA, US; 7Broward Gen Med Ctr, Fort Lauderdale, FL, US; 8Kaiser Fndn Res Inst, CA, US; and 9Massachusetts Gen Hosp, Harvard Med Sch, Boston, US |
944
|
Effects of Diet and Exercise and Rosiglitazone on Body Composition and Lipids, including Oxidized LDL in HIV+ and HIV- Men and Women
David Mun*1, E Engelson1,2, J Albu1,2, M Sharma2, T Pitea2, and D Kotler1,2
1Columbia Univ Coll of Physicians and Surgeons, New York, NY, US and 2St Luke`s Roosevelt Hosp Ctr, New York, NY, US |
945
|
Relationship between Polymerase Gamma Polymorphisms and ART-induced Lipodystrophy in HIV-infected Patients: A Case-Control Study
Franck Chiappini*, E Teicher, D Vittecoq, and A Lemoine
Hosp Paul Brousse, Villejuif, France |
946
|
Lipoatrophy and Lipohypertrophy Are Independently Associated with Hypertension: The Effect of Lipoatrophy but not Lipohypertrophy on Hypertension Is Independent of Obesity
Heidi Crane*1, C Grunfeld2, R Harrington1, and M Kitahata1
1Univ of Washington, Seattle, US and 2Univ of California, San Francisco, US |
947
|
Incidence of Lipodystrophy and Metabolic Syndrome after the Initiation of Combined ART in Sub-Saharan cART-naive Patients
Serge Eholie*1, K Lacombe2,3,4, L Denoeud4, C Adje1, F Cao4, O Bouchaud5, L Slama6, R Landmann7, E Bissagnene1, and P M Girard3,4
1Hosp de Treichville, Abidjan, Côte d`Ivoire; 2INSERM UMR S707, Paris, France; 3Univ Pierre and Marie Curie, Paris, France; 4Hosp St Antoine, Paris, France; 5Hosp Avicenne, Bobigny, France; 6Hosp Tenon, Paris, France; and 7Hosp Bichat, Paris, France |
| 948 |
Evaluation of Pregnancy PBMC and Placental MtDNA in HIV-infected, HAART-treated Women, Compared to HIV-uninfected Women
Helene Cote*1,2, E Maan3, E Papp1, T Chaworth-Musters3, I Gadawski1, J van Schalkwyk3, M Jitratkosol3, J Forbes3, D Burdge3, D Money2,3, and The HIV Perinatal Study Group
1Univ of British Columbia, Vancouver, Canada; 2Women`s Hlth Res Inst, Vancouver, Canada; and 3Children`s and Women`s Hlth Ctr of BC, Vancouver, Canada |
|
